Small size, big impact

Small molecule drugs have stood the test of time as the preeminent pharmaceutical method for treating patients. What this also means is that competition in the space is fierce, and every advantage matters – both in terms of manufacturing costs and product performance. Bill McCarthy, director of marketing at SPI Pharma, explains how the company’s S-Tab tablet platform offers both of these advantages, as well as enabling companies to bring products to market and scale them faster.